Transaction DateRecipientSharesTypePriceValue
6th January 2021Jerome B Zeldis1,650Grant/award etc.$0.00
28th May 2020Jerome B Zeldis1,000Open or private purchase$10.49$10,488.90
29th January 2020Jerome B Zeldis1,650Grant/award etc.$0.00
19th November 2019Christopher J Schaber10,770Open or private purchase$0.93$10,016.10
19th November 2019Jerome B Zeldis2,000Open or private purchase$0.93$1,850.00
23rd September 2019Diane L. Parks14,940Open or private purchase$0.93$13,870.30
19th September 2019Jerome B Zeldis4,000Open or private purchase$0.94$3,740.00
28th June 2019Mark E. Pearson78,338Grant/award etc.$0.71$55,619.98
22nd May 2019Jerome B Zeldis1,097Exercise of derivative$6.85$7,514.45
22nd May 2019Jerome B Zeldis20,000Exercise of derivative$3.40$68,000.00
Soligenix logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Soligenix, Inc. engages in the development and commercialization of products to treat rare disease. The company operates through the following segments: BioTherapeutics and Vaccines/BioDefense. It offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of T-cell lymphoma.

Ticker: SNGX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 812796
Employees: 16
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags